Cardiovascular Imaging Systems
This article was originally published in The Gray Sheet
Executive Summary
Completes secondary offering, netting approximately $5.2 mil. from the sale of 1 mil. shares at $6 each. The firm will use the proceeds primarily for research and development. CVIS says that it currently is supporting several studies related to its intravascular imaging technology (see story, p. 25). The firm also is working on the development of additional catheters for intravascular diagnostic and combined imaging/angioplasty uses. Montgomery Securities and Volpe, Welty & Company managed the offering, which initially was to be for 2 mil. shares ("The Gray Sheet" Feb. 1, p. 14).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.